Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | APLNR | P35414 | 1/20 | 0.45 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.44 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | TYR | P14679 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.42 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29684654 | 1.00 | ADRA2A (0.49) | ADRA2AADRA1AMEN1KMT2AAPLNR | |
| SCHEMBL28264992 | 0.92 | MEN1 (0.42) | ADRA2AADRA1AMEN1KMT2AAPLNR | |
| SCHEMBL29684861 | 0.89 | BCHE (0.49) | ADRA2AADRA1AMEN1KMT2AAPLNR | |
| SCHEMBL2965867 | 0.89 | BCHE (0.49) | ADRA2AADRA1AMEN1KMT2AAPLNR | |
| SCHEMBL2976761 | 0.81 | STAT3 (0.56) | ADRA2AADRA1AADRB2 | |
| SCHEMBL16504443 | 0.76 | ADRA2A (0.51) | ADRA2AADRA1AMEN1KMT2AADRB2 | |
| SCHEMBL7149085 | 0.76 | ADRA1A (0.70) | ADRA2AADRA1AMEN1KMT2AADRB2 | |
| SCHEMBL6291795 | 0.74 | ALDH1A1 (0.46) | MEN1KMT2AAPLNRTAS1R3TAS1R1 | |
| SCHEMBL29290893 | 0.73 | ESR1 (0.69) | APLNRTYR | |
| SCHEMBL266620 | 0.73 | HTR2A (0.57) | ADRA1AMEN1KMT2AAPLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210085580-A1 | DIARYLALKANES AS POTENT INHIBITORS OF BINUCLEAR ENZYMES | UNIGEN, INC. (US) | 2021-03-25 | — | — | US | claimed |
| US-20200170907-A1 | DIARYLALKANES AS POTENT INHIBITORS OF BINUCLEAR ENZYMES | UNIGEN, INC. (US) | 2020-06-04 | — | — | US | claimed |
| US-20160193126-A1 | DIARYLALKANES AS POTENT INHIBITORS OF BINUCLEAR ENZYMES | UNIGEN INC (US) | 2016-07-07 | — | — | US | claimed |
| EP-1748767-A4 | DIARYLALKANES AS POTENT INHIBITORS OF BINUCLEAR ENZYMES | UNIGEN PHARMACEUTICALS INC (US) | 2008-12-24 | — | — | EP | claimed |
| US-20080132581-A1 | particularly tyrosinase; preventing and treating melanin overproduction; isolated from a plant family selected from the group consisting of Compositae, Fabaceae, Lauraceae, Leguminosae, Liliaceae, Loranthaceae, Moracea, and Myristicaceae | UNIGEN PHARMACEUTICALS, INC. (US) | 2008-06-05 | — | — | US | claimed |
| EP-1748767-A1 | DIARYLALKANES AS POTENT INHIBITORS OF BINUCLEAR ENZYMES | Unigen Pharmaceuticals, Inc. (US) | 2007-02-07 | — | — | EP | claimed |
| WO-2005117849-A1 | DIARYLALKANES AS POTENT INHIBITORS OF BINUCLEAR ENZYMES | UNIGEN PHARMACEUTICALS, INC. (US) | 2005-12-15 | — | — | WO | claimed |
| US-20050267047-A1 | Diarylalkanes as potent inhibitors of binuclear enzymes | UNIGEN PHARMACEUTICALS, INC. (US) | 2005-12-01 | — | — | US | claimed |
| US-11857657-B2 | Diarylalkanes as potent inhibitors of binuclear enzymes | UNIGEN, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11857657-B2 | Diarylalkanes as potent inhibitors of binuclear enzymes | UNIGEN, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11857657-B2 | Diarylalkanes as potent inhibitors of binuclear enzymes | UNIGEN, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| CN-109134205-B | Diarylalkanes as potent inhibitors of binuclear enzymes | 尤尼根公司 | 2022-07-19 | — | — | CN | disclosed |
| US-20210085580-A1 | DIARYLALKANES AS POTENT INHIBITORS OF BINUCLEAR ENZYMES | UNIGEN, INC. (US) | 2021-03-25 | — | — | US | disclosed |
| US-20210085580-A1 | DIARYLALKANES AS POTENT INHIBITORS OF BINUCLEAR ENZYMES | UNIGEN, INC. (US) | 2021-03-25 | — | — | US | disclosed |
| US-20080132581-A1 | particularly tyrosinase; preventing and treating melanin overproduction; isolated from a plant family selected from the group consisting of Compositae, Fabaceae, Lauraceae, Leguminosae, Liliaceae, Loranthaceae, Moracea, and Myristicaceae | UNIGEN PHARMACEUTICALS, INC. (US) | 2008-06-05 | — | — | US | disclosed |
| US-20080132581-A1 | particularly tyrosinase; preventing and treating melanin overproduction; isolated from a plant family selected from the group consisting of Compositae, Fabaceae, Lauraceae, Leguminosae, Liliaceae, Loranthaceae, Moracea, and Myristicaceae | UNIGEN PHARMACEUTICALS, INC. (US) | 2008-06-05 | — | — | US | disclosed |
| US-20080132581-A1 | particularly tyrosinase; preventing and treating melanin overproduction; isolated from a plant family selected from the group consisting of Compositae, Fabaceae, Lauraceae, Leguminosae, Liliaceae, Loranthaceae, Moracea, and Myristicaceae | UNIGEN PHARMACEUTICALS, INC. (US) | 2008-06-05 | — | — | US | disclosed |
| EP-1748767-A1 | DIARYLALKANES AS POTENT INHIBITORS OF BINUCLEAR ENZYMES | Unigen Pharmaceuticals, Inc. (US) | 2007-02-07 | — | — | EP | disclosed |
| WO-2005117849-A1 | DIARYLALKANES AS POTENT INHIBITORS OF BINUCLEAR ENZYMES | UNIGEN PHARMACEUTICALS, INC. (US) | 2005-12-15 | — | — | WO | disclosed |
| US-20050267047-A1 | Diarylalkanes as potent inhibitors of binuclear enzymes | UNIGEN PHARMACEUTICALS, INC. (US) | 2005-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200170907-A1 | DIARYLALKANES AS POTENT INHIBITORS OF BINUCLEAR ENZYMES | TYR, DDT, HAAO | ADRA2A 2645/4885ADRA1A 1528/4885MEN1 2314/4885 |
| US-20050267047-A1 | Diarylalkanes as potent inhibitors of binuclear enzymes | TYR, DDT, HAAO | ADRA2A 2645/4885ADRA1A 1528/4885MEN1 2314/4885 |
| US-20160193126-A1 | DIARYLALKANES AS POTENT INHIBITORS OF BINUCLEAR ENZYMES | TYR, DDT, HAAO | ADRA2A 2645/4885ADRA1A 1528/4885MEN1 2314/4885 |
| US-20210085580-A1 | DIARYLALKANES AS POTENT INHIBITORS OF BINUCLEAR ENZYMES | TYR, DDT, HAAO | ADRA2A 2645/4885ADRA1A 1528/4885MEN1 2314/4885 |
| US-20080132581-A1 | particularly tyrosinase; preventing and treating melanin overproduction; isolated from a plant family selected from the group consisting of Compositae, Fabaceae, Lauraceae, Leguminosae, Liliaceae, Loranthaceae, Moracea, and Myristicaceae | TYR, MAOA, CYP51A1 | ADRA2A 3006/4885ADRA1A 2801/4885MEN1 1988/4885 |
| US-11857657-B2 | Diarylalkanes as potent inhibitors of binuclear enzymes | TYR, DDT, HAAO | ADRA2A 2645/4885ADRA1A 1528/4885MEN1 2314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.